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Abstract Enhanced expression of the MYC transcription factor is observed in the majority of
tumors. Two seemingly conflicting models have been proposed for its function: one proposes that
MYC enhances expression of all genes, while the other model suggests gene-specific regulation.
Here, we have explored the hypothesis that specific gene expression profiles arise since promoters
differ in affinity for MYC and high-affinity promoters are fully occupied by physiological levels of
MYC. We determined cellular MYC levels and used RNA- and ChIP-sequencing to correlate
promoter occupancy with gene expression at different concentrations of MYC. Mathematical
modeling showed that binding affinities for interactions of MYC with DNA and with core promoter-
bound factors, such as WDR5, are sufficient to explain promoter occupancies observed in vivo.
Importantly, promoter affinity stratifies different biological processes that are regulated by MYC,
explaining why tumor-specific MYC levels induce specific gene expression programs and alter
defined biological properties of cells.
DOI: 10.7554/eLife.15161.001
Introduction
Deregulated expression of one of the three members of the MYC gene family (MYC, MYCN or
MYCL) is observed in the majority of human tumors (Dang, 2012; Meyer and Penn, 2008). A broad
body of evidence establishes that deregulated MYC expression causally contributes to multiple
aspects of tumor development and that tumors depend on enhanced expression of MYC for growth
and survival (Casey et al., 2016; Soucek et al., 2013).
MYC proteins are transcription factors that bind DNA as part of several protein complexes; best
understood is a dimeric complex of MYC with its partner protein MAX that activates transcription via
binding to a specific DNA motif termed E-box with a consensus sequence of CACGTG (Conacci-
Sorrell et al., 2014). To repress transcription, the binary MYC/MAX complex associates with a zinc
finger protein termed MIZ1 (Wiese et al., 2013). ChIP (chromatin-immunoprecipitation)
(Fernandez et al., 2003) and ChIP-sequencing experiments (Lin et al., 2012; Nie et al., 2012;
Sabo` et al., 2014) demonstrate the presence of MYC on virtually all promoters with an open chro-
matin structure as well as on thousands of enhancers and intergenic sites in multiple cell types, rais-
ing the question what the functional relevance of this broad binding might be.
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Given this global binding pattern, it is surprising that MYC-driven tumors can be recognized by a
specific set of up- and down-regulated MYC target genes that holds considerable prognostic and
therapeutic value (Sabo` et al., 2014; Walz et al., 2014). One hypothesis to explain this observation
suggests that MYC proteins globally enhance transcription. This has been termed the general ampli-
fier model (Lin et al., 2012; Nie et al., 2012) and is supported by observations that MYC can cause
an increase in total RNA and mRNA levels (Grandori et al., 2005; Hsu et al., 2015; Lin et al., 2012;
Nie et al., 2012). In this model, specific gene expression patterns arise indirectly due to feedback
and feedforward loops induced by general amplification. The alternative viewpoint suggests that
MYC proteins regulate specific genes and that global changes in RNA and mRNA levels occur indi-
rectly as a consequence of MYC-driven cell growth (Sabo` and Amati, 2014). To explain the contrast
between global binding and specific gene regulation, the latter model proposes that much of MYC
binding to chromatin is non-productive in terms of transcriptional regulation (Kress et al., 2015).
We show here that the divergent models can be reconciled with experimental observations with-
out the need to invoke productive and non-productive modes of DNA binding. We analyzed U2OS
cells that express a doxycycline-inducible allele of MYC (Elkon et al., 2015; Walz et al., 2014) and
characterized DNA binding and gene expression patterns at different levels of MYC. We showed
previously that doxycycline-induced overexpression of MYC in these cells establishes a gene expres-
sion signature, which closely resembles multiple established signatures of MYC target genes and
identifies expression signatures of patients with MYC amplification in tumors (Walz et al., 2014).
Hence, these cells represent a simple model system, in which the effect of physiological and tumor-
specific MYC levels can be compared and provide a tool to elucidate the mechanism(s) by which
activation of a globally binding transcription factor can result in regulation of specific and function-
ally relevant gene expression patterns.
eLife digest Genes with the potential to cause tumors and cancer are commonly called
oncogenes. One example of an oncogene encodes for a protein called MYC and many tumors
contain high levels of this protein. MYC is a transcription factor and studies of aggressive tumors
suggested that, like most other transcription factors, MYC binds to and regulates the activity of a
small number of genes in tumors. However, other studies went on to show that MYC actually binds
to thousands of genes and somehow only regulates a subset of them during tumor development.
Lorenzin et al. set out to understand how this process works by generating human cells in which
the concentration of MYC protein could be altered. In the experiments, the concentration was
varied from normal healthy levels to the high levels found in aggressive tumors. The amount of MYC
bound to genes and the extent to which it activated the genes inside these cells was also measured.
Lorenzin et al. found that increasing MYC levels from normal to tumor-specific levels did not
affect MYC binding at genes where the transcription factor was already strongly bound in normal
cells. Rather, MYC binding increased only at genes that were weakly bound in normal cells.
Consistent with this observation, only genes at which MYC was weakly bound in normal cells were
activated by increasing MYC levels. This observation suggests that increasing the concentration of
MYC protein from normal to tumor-specific levels “fills up” previously empty binding sites around
these genes with the transcription factor.
Lorenzin et al. also used mathematical modeling to understand how the concentrations of MYC in
normal and tumor cells might explain how MYC behaves in cells. Together, the results imply that the
MYC transcription factor regulates distinct sets of genes in normal and tumor cells according to how
much MYC is present. Further studies may show that the altered regulation of a tumor-specific set of
genes is important for tumor development and could use this new information to identify new
targets for treating MYC-driven tumors.
DOI: 10.7554/eLife.15161.002
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Results
MYC binding to chromatin appears saturated at certain sites
To determine the effect of changes in MYC levels on DNA binding and gene expression, we have
previously engineered U2OS cells to express a doxycycline-inducible allele of MYC (Figure 1A). We
chose U2OS cells because they have relatively low levels of endogenous MYC, despite being tumor
cells. To illustrate this point, we determined MYC levels in a number of normal and transformed
cells. Lysates of equal numbers of exponentially growing cells were probed by immunoblotting
(Figure 1B). The results show that U2OS cells express levels of MYC that are comparable to non-
transformed cells (IMEC, HMLE, MCF10A) and lower than those found in other tumor cell lines (HeLa
and HCT116). Notably, prolonged exposure (>3 days) to doxycycline and hence long-term ectopic
expression of MYC induces apoptosis in U2OS cells (Walz et al., 2014); therefore, all subsequent
analyses were performed 28–30 hr after addition of doxycycline.
ChIP-sequencing of MYC in U2OSTet-on cells had previously shown that endogenous MYC binds
to about 5,500 promoters and that this number increases to about 8,400 MYC-bound promoters
upon addition of doxycycline (Walz et al., 2014). Different peak calling programs (MACS14, SICER,
CCAT) with default parameters result in very similar peak numbers (Figure 1—figure supplement
1A,B). Reducing the stringency of peak calling resulted in a moderate increase in peak number but a
large increase in the number of negative peaks, suggesting that an analysis using default parameters
does not overlook a large number of significant peaks (Figure 1—figure supplement 1C). In agree-
ment with reports from other systems, we concluded that the promoters of the majority of all
expressed genes are bound by MYC. Surprisingly, individual promoters showed a wide range of
occupancies for endogenous MYC (Figure 1C–E), whereas the differences in occupancy by MYC
among promoters were much smaller after induction with doxycycline (Figure 1D,E). Promoters,
which are least strongly bound by endogenous MYC recruit most MYC upon overexpression (i.e.
VEGFA, Figure 1E), whereas the most strongly bound genes recruit no additional MYC (i.e. RPL8).
This prompted us to analyze whether the anti-correlation between occupancy by endogenous MYC
and recruitment of exogenous MYC is evident globally (Figure 1F). To this end, we determined the
relative MYC recruitment at each bound promoter by calculating the fold-change of MYC occupancy
in cells with exogenous and endogenous MYC levels. Genes were ranked according to these MYC
recruitment values and plotted against the respective occupancy of endogenous MYC (Figure 1F,
blue dots). Strikingly, genes, which are most weakly bound (mean: 89 tags), recruit MYC most
strongly (5.3-fold), whereas the most strongly bound genes (mean: 580 tags) show on average no
further MYC recruitment. Importantly, when MYC occupancy at exogenous MYC levels is analyzed
(Figure 1F, orange dots), all bins of genes are bound to a high extent. One way to explain this
observation is the hypothesis that genes strongly bound by endogenous MYC levels are fully occu-
pied (’saturated’) and hence exogenous MYC is preferentially recruited to weakly bound genes.
To test whether this explanation is correct, we made use of the observation that MYC/MAX heter-
odimers compete with MXD/MAX heterodimers and MAX homodimers for binding to their target
sites (Conacci-Sorrell et al., 2014). If promoters were fully occupied by MYC/MAX heterodimers,
one would predict that MXD proteins are completely displaced from these promoters. We tested
this prediction by ChIP assays on four genes using an anti-MXD6 (MNT) antibody (Figure 1G). Bind-
ing of MXD6 was barely detectable above background for the two genes (NPM1, NCL), which are
strongly occupied by endogenous MYC, and did not further decrease upon addition of doxycycline.
In contrast, MXD6 occupancy was higher for two genes (HSPBAP1, FBX32), which are poorly bound
by endogenous MYC, but strongly decreased upon induction of MYC. Taken together, the easiest
model to explain the data is to suggest that a few hundred of promoters are saturated by endoge-
nous MYC in U2OS cells and that overexpression of MYC leads to saturation of the majority of MYC-
binding sites in promoters (Figure 1F).
Absolute quantification of nuclear MYC allows an estimate of MYC
binding affinities
To understand whether the number of MYC molecules per cell in U2OS cells is able to saturate the
numerous genomic binding sites, we quantified the absolute expression levels of MYC. A carboxy-
terminal fragment of human MYC comprising amino acids 353 to 434 was purified to homogeneity
Lorenzin et al. eLife 2016;5:e15161. DOI: 10.7554/eLife.15161 3 of 35
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Figure 1. MYC saturates certain binding sites. (A) Immunoblot of MYC and Vinculin in U2OSTet-On cells treated with EtOH or with 1 mg/ml of
doxycycline. (B) Immunoblot of MYC and Vinculin in several transformed (U2OS, HeLa, HCT116) and untransformed cell lines (IMECs, HMLE, MCF10A,
Figure 1 continued on next page
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and its amount was determined using spectrometric methods (Figure 2—figure supplement 1A).
We then used defined quantities of this fragment to calibrate a series of immunoblots. After com-
plete transfer of both, the recombinant protein and cellular MYC (Figure 2—figure supplement
1B), membranes were probed with the 9E10 monoclonal antibody, which recognizes an epitope (E-
QKLISEEDL) corresponding to amino acids 410 to 419 of human MYC (Figure 2A, Figure 2—figure
supplement 1D–F). From triplicate experiments, we estimated that U2OS cells express approxi-
mately 100,000 molecules of endogenous MYC per cell and that this number increases to approxi-
mately 3x106 molecules of MYC upon induction with 1 mg/ml doxycycline (see calculations in
Supplementary file 1). We performed immunofluorescence to estimate the cell-to-cell variation in
MYC levels (Figure 2—figure supplement 2). Induction of MYC expression by doxycycline was also
observed in situ by immunostaining for MYC and showed that MYC is overexpressed in all cells (Fig-
ure 2—figure supplement 2A). Staining and quantification with three different antibodies demon-
strated that endogenous MYC levels vary less than +/  3.7-fold in 80% of all cells (EtOH, Figure 2—
figure supplement 2B,C) and less than +/  2.9-fold upon overexpression (doxycycline, Figure 2—
figure supplement 2D,E). Previous estimates found that two human tumor cell lines derived from
small cell lung cancer and multiple myeloma express up to 880,000 molecules of MYC per cell
(Lin et al., 2012), confirming that upon maximal induction with doxycycline most U2OS cells express
MYC levels comparable or slightly higher to levels found in human tumor cells.
We used the estimated number of cellular MYC molecules and the nuclear volume of U2OS cells
(Koch et al., 2014) to calculate the nuclear concentration of MYC. Knowing both the nuclear MYC
concentration and the occupancy of every promoter in cells at endogenous and exogenous MYC lev-
els (ChIP-sequencing +/  doxycycline) allowed us to estimate affinities for all MYC bound pro-
moters. We calculated the concentration of MYC required for half-maximal occupancy of each
promoter (EC50) and used it as a measure for the apparent binding affinity (Figure 2B). Promoters
with low EC50 values showed a high, and those with high EC50 values a low binding affinity toward
MYC. A density plot illustrates that EC50 values of individual promoters vary over a large concentra-
tion range (Figure 2C).
To better understand the functional significance of the differences in promoter affinity, we used a
modified gene set enrichment (GSE) analysis (Subramanian et al., 2005), which uses EC50 rather
than expression values to test whether different biological processes can be stratified by promoter
affinity towards MYC. In this analysis, promoters of MYC target genes that encode functionally
related proteins are enriched if they exhibit similar EC50 values. Notably, genes encoding ribosomal
proteins (RPs) showed the lowest EC50 values, followed by genes encoding proteins involved in bio-
synthetic processes, translation and ribosome biogenesis (Figure 2D; gene sets are shown in
Supplementary file 2). These genes are thought to comprise a core signature of highly expressed
MYC target genes (Ji et al., 2011). At the other extreme, genes encoding metabolite transporters,
G-protein coupled receptors and genes involved in TGF-beta signaling and in the response to hyp-
oxia are among those with the highest EC50 values (Figure 2E). We hypothesized that differences in
Figure 1 continued
HEK293). For each sample, 60,000 cells were loaded. A quantification is shown at the bottom. (C) Heat maps for binding of endogenous MYC in
U2OSTet-On cells to all UCSC annotated promoters in a window of 5 kb around the transcriptional start site (TSS). Input is shown as control and intensity
of color indicates binding strength. (D) ChIP-sequencing traces of MYC for one genomic region as an example. Input is shown as control. (E) ChIP-
sequencing traces of MYC for four bound genes. RPL8 is a ribosomal protein, UTP15 and FBL are ribosomal biogenesis factors and VEGFA takes part in
cellular signaling. A scale bar is shown at the top of each browser picture. (F) Binned plot for the comparison of MYC recruitment (change in occupancy,
x-axis) and MYC occupancy (y-axis) in U2OSTet-On cells expressing endogenous levels of MYC (EtOH, blue dots) or overexpressing MYC (Dox, orange
dots). 8,425 genes bound by MYC upon treatment with doxycycline were sorted according to MYC recruitment and divided in 20 equally sized bins.
Each dot represents the average value of the bin. The bins containing the genes shown in panel E are indicated. (G) Quantitative ChIP experiments for
MYC (left panel) and MXD6 (right panel) at four MYC target genes and a control region. IgG were used as control. U2OSTet-On were treated either with
EtOH or with 1 mg/ml doxycycline to induce exogenous MYC expression. Data are shown as mean ± standard deviation of technical triplicates.
DOI: 10.7554/eLife.15161.003
The following figure supplement is available for figure 1:
Figure supplement 1. Effect of different peak calling programs and parameters on peak numbers.
DOI: 10.7554/eLife.15161.004
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Figure 2. MYC binds with a wide range of affinity (EC50 values) to target genes. (A) Immunoblot of MYC in U2OS
Tet-On cells treated with 1 mg/ml
doxycycline and a recombinant MYC protein fragment, which was used for absolute quantification of cellular MYC levels (M: marker). Absolute
Figure 2 continued on next page
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promoter affinity enable distinct concentrations of MYC to regulate functionally different sets of tar-
get genes.
Binding to DNA and to WDR5 accounts for high promoter affinity
Given the high variation in EC50 values, we wondered which factors account for promoter affinity
towards MYC. In a complex with MAX, MYC directly contacts E-box sequences in DNA. We initially
tested whether the known DNA binding properties of MYC/MAX heterodimers can explain the
EC50 values measured in ChIP-sequencing experiments. The heterodimer makes both base-specific
contacts and contacts to the phosphate backbone of DNA and hence binds to canonical E-boxes
(CACGTG), non-canonical E-boxes (CANNTG) and DNA with a random sequence (Nair and Bur-
ley, 2003). We modeled the binding behavior of MYC assuming canonical E-boxes and unspecific
binding sites at random DNA sequences, which are in excess over the canonical E-boxes (model 1,
Figure 3A, Appendix 1). This model ignores competition of MYC/MAX heterodimers with other
E-box binding proteins with the same binding specificity, such as MXD/MAX complexes, as well as
MITF, USF and TFE-3 (Conacci-Sorrell et al., 2014). We explored how the occupancy of canonical
E-boxes in the experimentally determined range of cellular MYC concentrations depends on the
dissociation constants of MYC reversibly binding to canonical E-boxes (KEbox) or unspecific binding
sites (KNNNNNN) (Figure 3B; note that all simulations show steady state solutions discussed in
Appendix 1). The simulations demonstrate that occupancies of canonical E-boxes above 90% can
be observed for certain combinations of dissociation constants. In contrast, occupancy of unspecific
binding sites is much smaller than 1% in the considered parameter space (Figure 3C) illustrating
that the number of unspecific binding sites strongly exceeds the number of canonical E-boxes
(Appendix 1). The model assumes that the entire genome is accessible and not blocked due to
heterochromatin formation. An extended analysis investigating the impact of heterochromatin
(Appendix 2) confirms that our assumption on genome accessibility hardly affects our presented
results and conclusions. Values of dissociation constants have been previously determined for
canonical E-boxes and for DNA with a non-E-box sequence. We fixed the dissociation constants in
our subsequent model analyses to one pair of published values (Guo et al., 2014) (see red and
blue lines in Figure 3B,C). The respective occupancies of canonical E-boxes and unspecific binding
sites in the experimentally determined range of total MYC abundance are shown in Figure 3D
(red and blue lines, respectively). Under these assumptions, MYC/MAX complexes are predicted to
bind canonical E-boxes with a calculated EC50 value of 1x10
2 mM (Figure 3D). Comparison with
the experimentally determined EC50 values showed that only 363 of 8,425 promoters show this or
a higher EC50 value.
The majority of E-boxes located in promoters showed considerably lower EC50 values than those
predicted by the affinity to E-box-DNA, indicating that binding to DNA alone is not sufficient to
account for the chromatin occupancy of MYC observed by ChIP-sequencing. Model simulations pre-
dict that a reduction of the dissociation constant of MYC and E-boxes by about one order of magni-
tude shifts the EC50 value into the measured range of MYC molecules (Figure 3E). To explore
potential underlying molecular mechanisms, we searched for features, which identify promoters with
Figure 2 continued
quantification is based on biological triplicates shown in Figure 2—figure supplement 1D–F. (B) Diagram of MYC occupancy calculated in ChIP-
sequencing experiments of EtOH- or doxycycline-treated U2OSTet-On cells (y-axis) versus the cellular MYC concentration (x-axis). The line was fitted
using a Michaelis-Menten model and non-linear regression. (C) Density plot of the distribution of the EC50 values calculated for all MYC-bound genes.
Dashed lines indicate the cellular MYC concentration in uninduced (EtOH, blue line), 1 mg/ml doxycycline treated (Dox, dark blue line), or MYC-
depleted (siMYC, light blue) U2OSTet-On cells. (D, E) GSE analysis using the MSigDB C5 (GO gene sets) collection, of genes sorted according to EC50
values. Enrichment plots of two gene sets enriched in the GSE analysis are shown as examples. NES: normalized enrichment score. Both, gene sets with
very low (D) and very high (E) EC50 values are shown.
DOI: 10.7554/eLife.15161.005
The following figure supplements are available for figure 2:
Figure supplement 1. Quantification of MYC molecules per U2OS cell.
DOI: 10.7554/eLife.15161.006
Figure supplement 2. Variation of MYC levels within the cell population demonstrates validity of the model conclusions for the majority of cells.
DOI: 10.7554/eLife.15161.007
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Figure 3. Binding behavior of MYC in U2OS cells analyzed by mathematical modeling. (A) Schematic representation of model 1. For details see
Appendix 1. (B, C) Plot illustrating regions of occupancy in the parameter space of dissociation constants KEbox and KNNNNNN as well as total amount of
Figure 3 continued on next page
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high affinity for MYC. Consistent with the DNA binding properties, we found a strong correlation
between the occupancy of endogenous MYC and the occurrence of canonical E-box sequences in
the binding region (Figure 4A, Figure 4—figure supplement 1A–F). In contrast, non-consensus
E-box sequences are only moderately enriched in MYC peaks and their frequency does not positively
correlate with MYC binding (Figure 4—figure supplement 1B,D-F). In addition to canonical E-box
sequences in the binding region, occupancy by endogenous MYC positively correlated with overall
expression of the respective gene (Figure 4B) and with features of open chromatin, such as trimethy-
lation of histone H3K4 (Figure 4C). This observation is in agreement with several previous reports
(Guccione et al., 2006; Guo et al., 2014; Lin et al., 2012; Nie et al., 2012). Recent work has identi-
fied WDR5, a WD40-repeat-containing protein, which is a part of the MLL/SET methyltransferases
that methylate H3K4 and the MOF/NSL histone acetyltransferases that acetylate histone H4, as a
direct interaction partner of MYC (Thomas et al., 2015). MYC binds to WDR5 with a KD of 9.3 mM
via MYC BoxIII (Thomas et al., 2015), a domain that is not part of the DNA-binding domain, sug-
gesting that binding of MYC to WDR5 occurs independently of binding to DNA. A modified model
(model 2; Figure 3F; see also Appendix 1) that assumes (i) that WDR5 is constantly bound to its tar-
get sites (ii) that MYC and WDR5 are free to bind to each other when both are bound to chromatin
in close proximity predicts an EC50 value of 0.014 mM for MYC occupancy of an E-box in the pres-
ence of WDR5 (Figure 3G). This value is lower than the one estimated experimentally for the large
majority of promoters, arguing that the MYC/WDR5 interaction is of sufficient high affinity to explain
the high occupancy of promoters with low EC50 values (7,963/8,425).
The model predicts that occupancy by MYC is strongest at promoters containing both E-boxes
and WDR5-binding sites but is also high for promoters bound by WDR5 but lacking E-boxes (EC50
value of 0.27 mM; Figure 3G, yellow curve). This prediction could be confirmed by stratifying all
MYC bound promoters in U2OS cells by these features and analyzing the individual groups for
occupancy by endogenous MYC, functional annotation and expression (Figure 4—figure supple-
ment 2A–C). Promoters bound by WDR5 and containing consensus E-box sequences are most
strongly bound by MYC (Figure 4—figure supplement 2A), enriched in genes encoding for
nuclear proteins (Figure 4—figure supplement 2B) and are associated with high expression (Fig-
ure 4—-figure supplement 2C). The two central predictions of the model are that (i) binding sites
are little occupied at cellular MYC concentrations if only the affinity of MYC to E-boxes is consid-
ered (Figure 3G, red curve), and that (ii) the occupancy strongly increases if the interaction of
MYC with WDR5 is considered in addition (Figure 3G, green curve). These predictions are valid
for at least 80% of cells when the cell-to-cell variation in the population is taken into account (Fig-
ure 2—figure supplement 2F).
To test the notion that the interaction between MYC and WDR5 is critical for the high occupancy
of some promoters, we re-analyzed published ChIP-sequencing data, performed in HEK293 cells, for
WDR5, wild-type MYC and a mutant allele of MYC (’MYCWBM’), which is strongly compromised in
binding to WDR5 (Thomas et al., 2015). In agreement with the published data, our re-analysis
showed that (i) the majority of promoters is bound by WDR5, (ii) almost all binding sites of MYC in
promoters overlap with WDR5 binding and (iii) disruption of the interaction between MYC and
Figure 3 continued
MYC. The grey area indicates the experimentally available concentration range, that is, EtOH to 1 mg/ml doxycycline (Dox) treatment. Regions of 1, 10,
50 and 90% occupancy of E-boxes (B) as well as 0.01% and 0.1% occupancy of NNNNNN sequences (C) are shown. The red line (B) and blue line (C)
give the combination of the particular dissociation constants published by Guo et al. (2014). (D) Simulations show that occupancy of E-boxes (red line)
by MYC is less than 10% in the measured range of MYC (grey area) while occupancy of NNNNNN (blue line) is below 1%. The EC50, which is the
concentration of total MYC to obtain 50% occupancy, is calculated to be 1x102 mM for E-boxes. (E) The EC50 of E-boxes (1x10
2 mM estimated in D) can
be reduced by decreasing the value of KEbox. Simulations predict that a reduction of KEbox (value published by Guo et al., 2014, is indicated by the
dashed line) by about one order of magnitude already shifts the EC50 into the measured range of MYC (grey area). (F) Schematic representation of
model 2. For details see Appendix 1. (G) In model 2, a reduction of the apparent dissociation constant of MYC and E-boxes as well as that of MYC and
unspecific DNA sites are assumed by means of additional regulatory proteins such as WDR5. In the presence of WDR5, occupancy of E-boxes by MYC
is above 95% (green line, EC50= 1.4x10
-2 mM) and occupancy of unspecific DNA sites by MYC is above 50% (yellow line, EC50 =2.7x10
–1 mM). Occupancy
of E-boxes or unspecific DNA sites that are not bound by WDR5 (red and blue line, respectively) remain however below 10% and 1%, respectively, in
the measured range of MYC (grey area).
DOI: 10.7554/eLife.15161.008
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Figure 4. E-box occurrence, expression level and chromatin status of target genes influence MYC binding. (A) Binned plot for the number of genes in
each bin with a canonical E-box (CACGTG) in the MYC peak versus MYC occupancy in U2OSTet-On treated with EtOH. Genes were sorted according to
Figure 4 continued on next page
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WDR5 strongly decreases MYC binding to chromatin (Figure 4D). Strikingly, analysis of MYCWBM
binding in HEK293 cells showed that eliminating MYC’s ability to interact with WDR5 most strongly
affects high-affinity binding sites with low EC50 values (Figure 4E). We conclude that known interac-
tions of MYC with DNA together with promoter-bound factors can account for the range of pro-
moter occupancies observed in vivo.
Since target gene expression, H3K4me3 and the occurrence of E-box sequences stratify high-
affinity binding sites (Figure 4A–C, Figure 4—figure supplement 1G,H), we wondered whether this
correlation also holds true for MYC that is recruited to promoters upon doxycycline induction.
Importantly, we found a strong anti-correlation between the recruitment of exogenous MYC on one
hand and the occurrence of E-boxes (Figure 4F), the expression level of target genes (Figure 4G)
and trimethylation of histone H3K4 (Figure 4H) on the other hand. This highlights that the major
change in occupancy is due to MYC binding to low-affinity binding sites and to weakly expressed
genes when MYC levels increase.
Binding affinity determines MYC-mediated transcriptional responses at
different MYC concentrations
Previously, we found that genes encoding ribosomal proteins and proteins involved in ribosomal bio-
genesis are not regulated in response to doxycycline-mediated MYC overexpression (Walz et al.,
2014), supporting the hypothesis that MYC binding sites in their promoters are fully occupied by
MYC at endogenous levels. To exclude the possibility that these genes are not regulated by MYC in
U2OS cells, we depleted endogenous MYC in U2OS cells by siRNA and analyzed gene expression
by RNA-sequencing (Figure 5A–D) and MYC binding by ChIP-sequencing (Figure 5—figure supple-
ment 1A–G). RNA-sequencing identified 753 genes being down- and 1224 genes being significantly
up-regulated (log2FC <  1 or > 1, q-value < 0.01, Figure 5B). Expression data were analyzed by
GSEA to identify functional groups of MYC-regulated genes. Strikingly, ribosomal protein genes and
genes encoding proteins involved in ribosomal biogenesis are most strongly down-regulated upon
siRNA treatment (Figure 5C,D). Accordingly, ChIP-sequencing upon depletion of MYC (Figure 5—
figure supplement 1A,C) demonstrated global loss of MYC binding to high-affinity binding sites
(Figure 5—figure supplement 1B,D) including promoters of ribosomal protein genes (Figure 5—
figure supplement 1E,F). Strikingly, genes, which show the highest affinity for MYC, most strongly
respond to depletion of endogenous MYC (Figure 5—figure supplement 1G). We confirmed our
previous observations that these gene sets are not regulated when MYC is overexpressed
(Figure 5E). To test whether similar dose-dependent transcriptional responses to MYC are also
observed during tumorigenesis, we utilized data from a murine model for MYC-driven B cell lympho-
magenesis (Figure 5F–H) (Sabo` et al., 2014). Expression profiles are published for three different
conditions, (i) resting B cells expressing only low levels of endogenous MYC (’control’), (ii) proliferat-
ing B cells expressing intermediate levels of MYC from the Em-MYC transgene (’pre-tumor’) and (iii)
Figure 4 continued
MYC occupancy and divided into 20 bins. Each dot represents the average of 422 genes. (B) Binned plot as in A, but with the mRNA expression of the
respective gene. Reads per kilobase per million (rpkm) are shown on the y-axis. (C) Binned plot as in A, but with H3K4me3 status of the respective
gene. (D) Venn diagram displaying the promoter-close (+/  5 kb) binding site overlap of WDR5, wild-type MYC (top), and a MYC mutant, which is
compromised in binding to WDR5 (’MYC mut’, bottom). Both, wild-type and mutant MYC were fused to a Flag epitope and stably expressed in HEK293
cells by Thomas et al. (2015). (E) Binned plot for MYC binding vs EC50 values. Genes bound by MYC in U2OS cells were sorted according to their EC50
values and correlated to average occupancy of a MYC mutant compromised in binding to WDR5 (blue dots) or wildtype MYC (orange dots). Values for
IgG are shown as a background control (grey dots). Panel D and E are re-analyses based on published data (Thomas et al., 2015). (F) Binned plot for
the number of genes in each bin having a canonical E-box (CACGTG) in the MYC peak versus MYC recruitment. Genes were sorted according to MYC
recruitment and divided in 20 bins. Each bin represents 422 genes. (G) Binned plot as in F, but the mRNA expression of the respective gene. Reads per
kilobase per million (rpkm) is shown on the y-axis. (H) Binned plot as in F, but H3K4me3 status of the respective gene was analyzed.
DOI: 10.7554/eLife.15161.009
The following figure supplements are available for figure 4:
Figure supplement 1. E-box occurrence and level of expression correlate with MYC binding and EC50 values.
DOI: 10.7554/eLife.15161.010
Figure supplement 2. Promoters that are bound by WDR5 and contain E-boxes are most strongly occupied by MYC.
DOI: 10.7554/eLife.15161.011
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Figure 5. Promoter affinity for MYC stratifies functionally different gene sets. (A) Immunoblot of MYC upon transfection of U2OSTet-On cells with the
indicated siRNA. Vinculin was used as loading control. (B) Plot for regulation of genes upon siRNA-mediated depletion of MYC vs relative expression
Figure 5 continued on next page
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transformed B cells selected for very high MYC expression (Sabo` et al., 2014). Strikingly, ribosomal
protein genes, hence the genes with lowest EC50 values, are strongly induced when the pre-tumor
condition is compared to control cells (Figure 5F,H). In contrast, expression of ribosomal protein
genes does not increase further when tumors are compared with pre-tumor cells (Figure 5G,H),
although MYC protein levels increase about eight fold (Sabo` et al., 2014). Conversely, some genes
that are regulated by exogenous MYC in U2OS cells and have low-affinity promoters, like those
encoding transmembrane transporters, are also regulated when comparing the tumor to pre-tumor
condition in B cell lymphomagenesis (Figure 5—figure supplement 1H,I). Therefore, we propose
that selective transcriptional responses by MYC at physiological and oncogenic levels are similar in
vivo and in vitro.
To further explore the correlation between binding affinity and selective transcriptional
responses, we compared median EC50 DNA binding values of gene sets that respond to depletion
of endogenous MYC to EC50 values of gene sets that are regulated in response to MYC overexpres-
sion (Figure 5I). Gene sets, which are strongly regulated upon overexpression, for example, genes
involved in angiogenesis and cell migration (Figure 5I, orange boxplots), show a significantly higher
median EC50 value than gene sets derived from the depletion of endogenous MYC (Figure 5I, blue
boxplots). We noted that also genes involved in circadian rhythm are regulated upon MYC overex-
pression and showed high EC50 values, consistent with the recent demonstration that disruption of
the circadian clock is a critical transforming function of MYC (Altman et al., 2015). We concluded
that binding affinity determines specific MYC-mediated transcriptional responses at physiological
and oncogenic MYC concentrations. To further support this conclusion, we analyzed expression data
from embryonic fibroblasts isolated from mice that carry floxed MYC alleles (Perna et al., 2012).
Strikingly, EC50 values of genes that are down-regulated upon deletion of endogenous MYC are
very low (Figure 5I, green boxplot) confirming that, as in U2OS cells, at physiological levels MYC
regulates genes with the highest binding affinity. In view of reports, which demonstrate that altering
cellular metabolism is a transforming mechanism of MYC (Stine et al., 2015), we analyzed the affin-
ity of promoters of genes encoding proteins involved in selected metabolic processes and indeed
observed elevated EC50 values for lipid- and purine metabolism and potentially glycolysis (Figure 5I,
violet boxplots).
Increasing amounts of MYC gradually shift transcriptional programs
Our data suggest that MYC regulates different sets of genes at physiological and oncogenic levels
and that these gene sets can be stratified by promoter affinity. We wondered, if there are indeed
two distinct modes of regulation or if MYC-mediated responses rather vary continually upon changes
in cellular MYC concentrations. To test this, we gradually manipulated MYC levels in U2OSTet-On cells
by titrating the amount of doxycycline and calculated the absolute number of MYC molecules in trip-
licate experiments (Figure 6A, Figure 2—figure supplement 1D–F). Analysis of gene expression
profiles at five different concentrations of doxycycline revealed different response patterns for
Figure 5 continued
levels (known as M/A-plot). Red dots represent significantly regulated genes (q-value <0.01, q-values were estimated by Benjamini-Hoechberg-
corrected p-values calculated by EdgeR). The experiment was performed in biological triplicates. (C) GSE analysis comparing gene expression profiles
of siCtr- or siMYC-transfected U2OSTet-On cells. NES: normalized enrichment score. (D) Enrichment plot of the ’Structural constituent of ribosome’ gene
set found in C upon depletion of endogenous MYC by siRNA. (E) Enrichment plot of the same gene set as in D, but gene expression profiles of
U2OSTet-On cells uninduced (EtOH) or induced with 1 mg/ml doxycycline were used. (F-H) Gene expression analysis comparing the gene expression
profile of a ribosomal gene set in the Em-MYC model of B cell lymphomagenesis in three different conditions. Differential expression is shown by GSE
analysis comparing a pre-tumor condition to control condition (F) and a tumor condition to a pre-tumor condition (G) or by boxplots (H). Panel F to H
are re-analyses of published B cell expression profiles (Sabo` et al., 2014). (I) Boxplots of gene sets found in panel C (blue), genes regulated upon MYC
knockout in fibroblasts (green) (Perna et al., 2012), gene sets regulated by MYC overexpression (orange) (Walz et al., 2014) and selected metabolic
processes (violet). The y-axis shows EC50 values calculated as shown in Figure 2. p-values: One-sided Mann-Whitney-Wilcoxon test comparing the
indicated GO terms to the median of ’RNP complex’ (dashed line). Outliers not shown.
DOI: 10.7554/eLife.15161.012
The following figure supplement is available for figure 5:
Figure supplement 1. Changes in chromatin binding upon MYC depletion correlate with transcriptional responses.
DOI: 10.7554/eLife.15161.013
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Figure 6. MYC levels determine the regulation of different transcriptional response programs. (A) Bar plot indicating MYC levels in U2OSTet-On cells
treated with EtOH or with different concentrations of doxycycline. Data are shown as mean ± standard deviation of three independent biological
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different gene sets (Figure 6B), ranging from hardly any response to MYC overexpression (’structural
constituent of ribosome’), medium-level responses (’ribonucleoprotein complex biogenesis’), to
gene sets, which responded predominantly at very high MYC levels (’substrate-specific transporter
activity’). The RNA-sequencing data enabled us to calculate EC50 values for regulation and to corre-
late them with EC50 values for binding. Importantly, the observed differences in dose response cor-
relate with the promoter affinity of the genes involved in these processes (Figure 6C). We conclude
that differences in promoter affinity can account for the distinct transcriptional response programs
observed in biological systems exhibiting different MYC expression levels (Figure 7).
Repressed genes exhibit low affinity for MYC
Finally, a prominent discrepancy among reports analyzing the transcriptional consequences of MYC
level manipulation is the presence or absence of direct MYC-mediated repression (Lin et al., 2012;
Nie et al., 2012; Sabo` et al., 2014; Walz et al., 2014). As direct repression is most apparent at
high levels of MYC (Wiese et al., 2015), we hypothesized that differences in MYC expression levels
might explain this seeming contradiction. Direct MYC-mediated repression largely depends on com-
plex formation with MIZ1 (Peukert et al., 1997), which is strongly reduced when expressing a point
mutant of MYC (MYCV394D). By using previously published datasets (Walz et al., 2014), we identified
direct MYC-repressed sets of genes assuming that they are re-expressed if MIZ1 is depleted
(shMIZ1) or if MYCV394D instead of wild type MYC is expressed. Interestingly MYC/MIZ1-mediated
repression takes place at high levels of MYC, both in a global analysis (Figure 6D) as well as for indi-
vidual genes (Figure 6E). Accordingly, genes directly repressed by MYC (’Down (direct)’ in
Figure 6F), show significantly higher EC50 values than transactivated genes (’Up’), whereas indirectly
repressed genes (’Down (indirect)’ in Figure 6F) show affinities comparable to that of transactivated
genes. We concluded that direct MYC-mediated repression is a predominant form of transcriptional
regulation at high (oncogenic) levels of MYC, which may not be reached during normal cell growth
(Figure 7A).
Discussion
The aim of this study was to understand whether an analysis of MYC function at different protein lev-
els in combination with mathematical modeling can reconcile two seemingly conflicting observations:
Whereas MYC regulates specific genes in some biological settings (’specifier model’), in others MYC
enhances expression of all genes transcribed by RNA polymerase II (’amplifier model’). Our study
has led to two major conclusions.
The first conclusion is that direct interaction with DNA alone is not sufficient to account for the
observed occupancies of core promoters by MYC/MAX complexes. This result is in agreement with
experimental observations showing that the positions occupied by MYC/MAX complexes across
the human genome closely correlate with the RNA polymerase II transcription machinery even on
promoters, which do not contain E-boxes (Guccione et al., 2006; Guo et al., 2014). The
Figure 6 continued
replicates, which are shown in Figure 2—figure supplement 1D–-F. Table of calculated MYC molecules and concentration per cell (see
Supplementary file 1 for calculation). (B) Heat maps for regulation of genes belonging to the three gene sets (Structural constituent of ribosome:
GO_0003735; Ribonucleoprotein complex biogenesis: GO_0022613; substrate-specific transporter activity: GO_0022892) identified by GSEA in
Figure 2D,E and Figure 5C. For all conditions, log2FC was calculated relative to the EtOH sample and only transactivated genes are shown.
Supplementary file 2 contains gene set lists used in this study. (C) Plot for median EC50 values for binding and regulation of gene sets from Figure 5I.
EC50 values for regulation were calculated using RNA-sequencing data from the MYC depletion (Figure 5A) and the MYC titration experiments
(Figure 6A). (D) Heat maps documenting the regulation of genes down-regulated by wild-type MYC and derepressed by MYCV394D or in cells depleted
of MIZ1. Log2FC calculated as in B. (E) qRT-PCR analysis from U2OS
Tet-On induced for MYC overexpression with increasing doxycycline concentrations.
Both, MYC mRNA levels (x-axis) and mRNA levels of MYC target genes (y-axis) are plotted. Dashed lines indicate half-maximal gene regulation. Please
note the differences in MYC expression needed for half maximal target gene regulation between transactivated (orange curve) and repressed (blue
curve) genes. The x-axis shows MYC mRNA levels relative to the EtOH control. (F) Boxplots of genes repressed by wild-type MYC but not by MYCV394D
(MYCVD, ’Down (direct)’) or by wild-type MYC when MIZ1 is depleted via shRNA (shMIZ1, ’Down (direct)’). MYC-activated genes (’Up’) and genes, which
are repressed in the absence of a functional MYC/MIZ1 complex (’Down (indirect)’) were used as reference gene sets. p-values (p), One-sided Mann-
Whitney-Wilcoxon test. Outliers are not shown in the plot.
DOI: 10.7554/eLife.15161.014
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conclusion is based on a modeling approach that assumes two classes of binding sites, a high-affin-
ity class of binding sites with consensus E-boxes and a second class of binding sites containing
non-specific DNA. This assumption is an over-simplification, since MYC/MAX complexes have low
affinity for binding sites containing non-consensus E-box sequences, which exceeds the affinity for
non-specific DNA (Blackwell et al., 1993) (Figure 4—figure supplement 1E,F). Furthermore, mul-
tiple other transcription factors recognize the same consensus sequence as MYC/MAX proteins,
suggesting that there is significant competition for E-box binding among these complexes in cells
(Wolf et al., 2015). As a consequence, the current model overestimates the fraction of MYC/MAX
complexes bound to consensus E-boxes. These considerations reinforce the conclusion that DNA
binding alone cannot account for the high occupancies of core promoters by MYC/MAX complexes
in cells.
The mathematical analysis shows that the interaction of MYC/MAX with promoter-bound WDR5
can strongly enhance occupancy of core promoters. Consistent with this finding, a mutant allele of
MYC unable to bind to WDR5 shows much reduced binding to high-affinity promoters. MYC does
not only interact with WDR5, but with several components of the transcription machinery including
P-TEFb, TBP and TRRAP (Bouchard et al., 2004; Eberhardy and Farnham, 2002; Hateboer et al.,
1993; McMahon et al., 1998; Rahl et al., 2010). Additionally, we recently identified the interaction
of another conserved domain of MYC, MYC BoxI, with the PAF1C complex that is located at core
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promoters (Jaenicke et al., 2016). We restricted our analysis to WDR5, since no dissociation con-
stants for other protein/protein interactions of MYC have been published. However, MYC high-affin-
ity binding sites can be observed at genomic regions, which are not in proximity to WDR5 binding
sites, suggesting that other factors are involved in establishing MYC genomic binding pattern.
Future ChIP-sequencing studies of MYC upon depletion of MYC interaction proteins will clarify the
impact of individual factors on chromatin binding of MYC.
Most likely, therefore, genome-wide occupancies of MYC/MAX complexes result both from inter-
actions of MYC/MAX complexes with DNA and from protein/protein interactions with resident chro-
matin proteins. We propose that the dependence of MYC/MAX chromatin binding on interactions
with proteins that are themselves influenced by existing gene expression patterns at different physi-
ological states of cells, contributes to specific gene regulation by MYC even though MYC´s mecha-
nism of action is the same at all promoters (as an example, see Liu et al. (2015)). Our analysis leads
to the hypothesis that conserved protein/protein interactions of MYC are critical for targeting MYC/
MAX complexes to specific classes of binding sites such as core promoters in vivo.
The second conclusion that can be drawn from our data is that promoter affinity for MYC confers
specificity to gene regulation. Our results show that promoters differ in their apparent affinity for
MYC and demonstrate a close correlation between apparent promoter affinity measured by ChIP-
sequencing and response to different concentrations of MYC measured by RNA-sequencing at dif-
ferent MYC levels. This correlation leads to the conclusion that a gene is regulated by MYC in a
given experimental setting, if the occupancy of its promoter (or a relevant enhancer) by MYC
changes in this setting. Importantly, measurements of MYC levels and modeling approaches show
that promoters can be saturated by levels of MYC that are reached in proliferating cells (Figure 7A).
As a result, expression of genes may not respond to MYC in a certain experimental setting (such as
a doxycycline-mediated induction of high MYC levels) since the promoters are fully occupied before
addition of doxycycline. This is likely to be true for strongly transcribed genes as many ribosomal
protein genes and genes encoding proteins involved in ribosome biogenesis and translation. The
experimentally observed specificity in gene regulation can therefore be explained without the need
to invoke productive and non-productive modes of interaction of MYC with chromatin.
Consistent with this notion, the analysis of MYC-driven lymphomagenesis shows that MYC can
contribute to oncogenic transformation via two different mechanisms: low levels of constitutive MYC
enhance expression of genes with high-affinity promoters, such as genes encoding proteins involved
in ribosome function. This is seen when pre-tumorigenic B-cells are compared with control lympho-
cytes. MYC levels further increase at the transition to frank lymphomas and there is clear evidence
for further increases in MYC levels during progression of several tumor entities, as for example in
APC-mutant colorectal tumors (Kress et al., 2011; Myant and Sansom, 2011; Siemens et al.,
2011). This additional increase in MYC levels will enhance occupancy of promoters that are lowly
occupied in normal and proliferating cells. Since differences in apparent affinity and in EC50 values
stratify classes of promoters of genes that encode proteins that differ in function, we propose that
this will alter the physiological and metabolic state (Stine et al., 2015) of the tumor cells
(Figure 7B). Notably, promoters with the lowest apparent affinity are found in genes that encode
proteins involved in nutrient transport, G-protein coupled receptors and in the response to hypoxia.
Expression of these genes responds to further increases in MYC levels arguing that they are the
basis for the selective pressure for increases in MYC levels. Since many tumors depend on (’are
addicted to’) high MYC levels, inhibition of proteins encoded by this class of target genes can be a
rational strategy for selective inhibition of MYC-dependent tumor growth.
Finally, we note that virtually all genes that are repressed by MYC/MAX in complex with MIZ1 dis-
play low apparent affinities and high EC50 values, suggesting that MIZ1-mediated repression occurs
predominantly at high MYC levels. MIZ1-mediated repression is required for tumor formation in
MYC-driven lymphoma (van Riggelen et al., 2010) and medulloblastoma (Vo et al., 2016), suggest-
ing that targeting the complex may provide a second strategy with a significant therapeutic window
for MYC-dependent tumors.
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Materials and methods
Cell culture and transfection
U2OS, HeLa, HEK293 and HCT116 cells were cultivated in DMEM (Sigma-Aldrich, St. Louis, USA)
supplemented with 10% FCS (EMD Millipore, Billerica, USA) and 1% penicillin/streptomycin (Sigma-
Aldrich). IMECs and HMLE cells were cultivated in DMEM/F12 (co) supplemented with 1% penicillin/
streptomycin (Sigma-Aldrich), 10 mg/ml insulin (Sigma-Aldrich), 0.5 mg/ml hydrocortisone (Sigma-
Aldrich) and 20 ng/ml EGF (Life Technologies, Carlsbad, CA). MCF10A cells were cultivated in
DMEM/F12 (Thermo Fisher Scientific, Waltham, USA) supplemented with 5% horse serum (Sigma-
Aldrich), 10 mg/ml insulin (Sigma-Aldrich), 0.5 mg/ml hydrocortisone (Sigma-Aldrich) and 20 ng/ml
EGF (Life Technologies) and 100 ng/ml choleratoxin (Sigma-Aldrich). Cell lines were tested for myco-
plasma and authenticated by STR profiling (HCT116, MCF10A, HeLa, U2OS). They were not found
to be on the list of commonly misidentified cell lines (International Cell Line Authentication Commit-
tee, with the exception of HEK cells) and received from research labs, companies (HCT116: LGC
genomics) or public repositories (HEK293: ATCC).
For siRNA transfections, the RNAiMAX reagent (Thermo Fisher Scientific) and the Opti-MEM
medium (Thermo Fisher Scientific) were used following the manufacturers’ instructions. A pool of
siRNA against MYC (ON-TARGETplus SMARTpool MYC, L-003282-02-0020) and a control pool of
siRNA (ON-TARGETplus Non-targeting Pool, D-001810-10-20) were purchased from GE Healthcare.
Cells were harvested 48 hr after transfection.
Expression and purification of recombinant MYC protein
The mRNA sequence of the dimerization and DNA-binding domain of human MYC was cloned into
the pETM11 (EMBL-Heidelberg) vector. The protein was expressed as an N-terminally His-tagged
protein in ArcticExpress (DE3)RIL cells (Agilent Technologies, Santa Clara, USA) after an OD of 0.8
was reached by induction with 0.1 mM isopropyl-b-thiogalactoside (IPTG) at 14˚C for 18 hr. The pro-
tein was purified to homogeneity by metal affinity chromatography (Ni-NTA, Thermo Fisher Scien-
tific) followed by anion exchange chromatography (AEC). AEC was performed using a MonoQ 10/
100 GL column (GE Healthcare, Chicago, USA) equilibrated with 20 mM HEPES pH 8.0 and 0.25 M
NaCl. The protein did not bind to the column but eluted in the flow through. Size exclusion chroma-
tography was performed using a HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare) to
confirm its monomeric state and exclude aggregation. The protein was concentrated after AEC to
0.59 mg/ml based on the calculated extinction coefficient using ProtParam (SwissProt) and then flash
frozen adding 10% glycerol for storage.
Immunoblotting
Cells were either lysed in lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton-
X-100, 0.1% Sodium deoxycholate, 0.1% SDS) with protease and phosphatase inhibitor cocktails
(Sigma-Aldrich) or harvested by trypsinization, counted and lysed directly in SDS sample buffer. The
same number of cells or total protein amount was loaded for each sample on Bis-Tris or Tris-Glycine
gels and transferred to PVDF membranes (EMD Millipore, Billerica, USA).
To detect the MYC protein the 9E10 antibody (amino acids: 410–419) or the anti-MYC antibody
(Y69: N-terminus, Abcam, Cambridge, UK) were used. To detect Vinculin the V9131 anti-Vinculin
antibody (Sigma-Aldrich) was used.
The immunoblots were visualized and quantified using the LAS-4000 mini (Fujifilm, Tokyo, Japan)
or the Odyssey CLx Infrared Imaging System (LI-COR, Lincoln, USA).
The number of MYC molecules/cell was calculated by comparing the signal of recombinant MYC
protein with cell lysates from U2OS cells in biological triplicates in quantitative immunoblots
(Odyssey CLx Infrared Imaging System). To determine the nuclear MYC concentration, the size of
U2OS nuclei was obtained from (Koch et al., 2014). Biological replicates are defined by individual
U2OS cell harvestings.
Chromatin immunoprecipitation (ChIP)
ChIP and ChIP-sequencing was performed as described previously (Walz et al., 2014). Briefly, cells
were crosslinked with 1% formaldehyde for 10 min at room temperature. After extraction, nuclei were
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lysed in lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 0.1%
Sodium deoxycholate, 0.1% SDS). The cell lysates were sonicated to reach an average DNA fragment
size of 140-300 bp. Immunoprecipitation was performed 6 hours or overnight using Dynabeads
(Thermo Fisher Scientific). For MYC and MNT immunoprecipitation, the anti-MYC antibody (N262,
Santa Cruz, Dallas, USA) and the anti-MNT antibody (sc-769, Santa Cruz, Dallas, USA) were used,
respectively. After washing, chromatin was eluted, de-crosslinked and treated with RNase A and Pro-
teinase K. The DNA was purified by phenol/chloroform extraction and ethanol precipitation and ana-
lyzed by qPCR using MX3000P with Sybr green Mix (Thermo Fisher Scientific, ChIP) or sequenced on
a Next-Seq500 after library preparation (NEBNext ChIP-Seq Library Prep Master Mix Set, NEB, Ips-
wich, USA).
RT-qPCR
For RT-qPCR analysis, total cellular RNA was extracted using the peqGOLD TriFast (Peqlab, Erlan-
gen, Germany) reagent. The first strand synthesis was performed using M-MLV Reverse Transcrip-
tase (Thermo Fisher Scientific) and random hexamer primers (Roche, Basel, Switzerland). Results
were normalized to b2-microglobulin expression. Primers are listed in Supplementary file 3. Techni-
cal replicates are defined by performing individual qPCR-analyses (CT-value estimation) with the
same cDNA. Biological replicates are defined by individual U2OS cell harvestings.
RNA-sequencing
For RNA-sequencing, total RNA was extracted using the RNeasy mini columns (Qiagen, Hilden, Ger-
many) including on-column DNase I digestion. PolyA+-RNA was isolated from total RNA with the
NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB, Ipswich, USA). The NEBNext Ultra RNA
Library Prep Kit for Illumina was used for library preparation following the manufacturer’s instruction.
Size selection of the libraries was performed with the AMPure XP Beads (Beckman Coulter, Brea,
USA), followed by 12 PCR cycles for amplification. Library quantification and quality was assessed
using the Experion Automated Electrophoresis System (Bio-Rad, Hercules, USA). The libraries were
sequenced with the Illumina Genome Analyzer IIx (Illumina, San Diego, USA).
Immunofluorescence
U2OS cells were treated with doxycycline/ethanol and were fixed with 4% paraformaldehyde.
Fixed cells were treated with blocking solution (10% horse serum, 2% BSA and 5% sucrose in PBS)
for 45 min after washing. Primary antibodies were incubated overnight at 4˚C and incubated for
1 hr with the corresponding fluorescently labeled secondary antibodies at room temperature after
washing (Tris-buffered saline with 0.1% Tween-20). Cells were mounted on object glass slides using
aqua-fluoromount (Sigma) after washing and imaged under a confocal microscope (Nikon Ti-
Eclipse). For fluorescent intensity measurement, ImageJ 1.50hr (Schneider et al., 2012) was used.
Briefly, z stacked confocal images were converted to 12-bit images via maximum intensity projec-
tion and ROI assigned using ROI tool. The intensity was measured per cell nuclei for Hoechst and
MYC. The fold change distribution of MYC was calculated by first taking MYC intensity normalized
to Hoechst and then further normalizing the values to the median of the set of measurements.
Finally Log2 of the median normalized values were displayed as density plots on R using ’sm’
library density function.
Bioinformatic analyses
For RNA-sequencing, reads were aligned to the human reference genome (hg19) using BOWTIE
v.0.12.8. The obtained BAM files were used for further analysis with R/BioConductor. For differential
gene expression analysis EdgeR was employed. The rpkm values were calculated by mapping the
read counts to the exons of the corresponding gene. Heat maps showing the gene expression
changes were obtained using R.
ChIP-sequencing data were obtained from (Walz et al., 2014) and analyzed similarly. The MYC
peaks were visualized using the wig files from MACS v.1.4.2 (Feng et al., 2012) and the Integrated
Genome Browser software (Nicol et al., 2009). ChIP-sequencing samples from (Walz et al., 2014)
were sequenced deeper for visualizing purposes.
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Peak calling was performed with MACS v.1.4.2 (parameters: –keep-dup 3, variable p-value cut-
off), SICER v.1.1 (parameters: redundancy 1, window 200, fragment size 90, effective genome frac-
tion 0.74, gap 0, FDR 0.01) (Zang et al., 2009) and CCAT v.3.0 (parameters: default for transcription
factors) (Xu et al., 2010). Overlapping peaks were determined with the ’intersectBed’ function from
BEDTools v.2.17.0 (Quinlan, 2014). Promoter regions are defined as –1.5 kb to +0.5 kb relative to
the transcriptional start site if not indicated otherwise.
To analyze the occurrence of E-boxes in the MYC peak the CentriMo tool from the MEME Suite
(Bailey and Machanick, 2012) was used. The empirical probability of consensus and non-consensus
E-boxes was plotted with a moving average of 20 bp.
To calculate the distribution around the TSSs (heat maps) or the center of the MYC peak (occu-
pancy), Seqminer v.1.3.3 was used. Heat maps were visualized using Treeview. MYC and H3K4me3
occupancies (in – and + Dox) were calculated using a window of ± 100 bp for the center of the MYC
peak and used to obtain MYC recruitment. DNA binding of MYC and a mutant of MYC that is com-
promised in binding to WDR5, was analyzed similar: 5x107 reads were randomly chosen from fastq
files (GSE60897), mapped with BOWTIE and reads in a window of ± 100 bp around the center of the
MYC peak were counted using Seqminer. For Venn diagrams, publicly available peak annotations
(GSE60897) were used and the overlap was calculated using Bedtools. For binned plots, genes were
sorted and divided in equally sized-groups and the median or mean values are shown. As few genes
show very high EC50 values, sometimes one or two bins were not shown in the plots, for clarity.
EC50 values for MYC binding at each promoter were calculated using the MYC nuclear concentra-
tions and MYC occupancy in – and +Dox. MYC occupancy was calculated by subtracting the tag val-
ues of the input from the tag values of the MYC ChIP and resulting negative values were set to 0.
The Michaelis-Menten model was used to perform the fitting of the data in GraphPad Prism and to
calculate maximal occupancy of MYC and the EC50 values.
For the estimation of the EC50 values for regulation of MYC target genes, the MYC depletion
RNA-sequencing experiment and the Dox titration RNA-sequencing experiment were used. The fold
change of expression for each gene was calculated relative to siMYC. Only activated genes were con-
sidered. The EC50 values were obtained using the fold change values and the nuclear MYC concentra-
tions. Michaelis-Menten model was used to perform the fitting of the data in GraphPad Prism. To
statistically test the difference of the distribution of the EC50 values of different gene sets, the Mann-
Whitney-Wilcoxon test was used. For functional analysis of the genes, Gene Set Enrichment Analyses
(GSEA) were performed with the C5 collection of gene sets from the MSigDB (http://www.broadinsti-
tute.org/gsea/msigdb) using the GSEAPreranked tool, where indicated. Gene ontology analysis was
performed using DAVID (Huang et al., 2009) with default settings and gene ontology (GO) terms
from the domains ’cellular component’, ’molecular function’ and ’biological process’ as database.
Sample size was not estimated by statistical methods but chosen based on common standards.
Mathematical modeling
The temporal changes of the system’s components are described by sets of ordinary differential
equations (ODEs) and algebraic equations describing conservation relations. Model design, the par-
ticular equations and parameters are listed in the Appendix 1. An extended model analysis is pro-
vided in Appendix 2. Steady-state solutions were calculated by setting all time derivatives to zero
and solving the resulting algebraic equation system numerically. All calculations were performed
using Mathematica 10.2 (Wolfram Research, Inc.).
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Appendix 1
Appendix 1 provides the detailed description of the mathematical models 1 and 2. Schemes
of models 1 and 2 are provided in Appendix 1—figure 1.
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Appendix 1—figure 1. Schemes of models 1 and 2.
DOI: 10.7554/eLife.15161.019
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Model 1
Temporal change of MYC bound to DNA sequences
d MYC@Ebox½ 
dt
¼ v1  v1r (1)
d MYC@NNNNNN½ 
dt
¼ v2  v2r (2)
The hexamer sequence NNNNNN excludes the CACGTG sequence.
Assumed conservation relations
MYCtotal½  ¼ MYC½  þ MYC@Ebox½ þ MYC@NNNNNN½  (3)
Eboxtotal½  ¼ Eboxunbound½ þ MYC@Ebox½  (4)
NNNNNNtotal½  ¼ NNNNNNunbound½ þ MYC@NNNNNN½  (5)
Rates
v1 ¼ k1  MYC½   Eboxunbound½  (6)
v1r ¼ k 1  MYC@Ebox½  (7)
v2 ¼ k2  MYC½   NNNNNNunbound½  (8)
v2r ¼ k 2  MYC@NNNNNN½  (9)
Steady state assumption
d MYC@Ebox½ 
dt
¼ 0 (10)
d MYC@NNNNNN½ 
dt
¼ 0 (11)
The ratios of dissociation and association rate constant are substituted by the dissociation
constants KEbox ¼
k 1
k1
and KNNNNNN ¼
k 2
k2
.
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Model 2
Temporal change of MYC bound to DNA sequences
d MYC@Ebox½ 
dt
¼ v1  v1r (12)
d MYC@NNNNNN½ 
dt
¼ v2  v2r (13)
d MYC@EboxWDR5½ 
dt
¼ v3  v3r (14)
d MYC@NNNNNNWDR5½ 
dt
¼ v4  v4r (15)
MYC can reversibly bind to four independent classes of DNA binding sites: CACGTG
sequences (Ebox), unspecific DNA sequences (NNNNNN), WDR5 and CACGTG sequence
simultaneously (EboxWDR5), as well as WDR5 and unspecific DNA sequences simultaneously
(NNNNNNWDR5).
Assumed conservation relations
MYCtotal½  ¼ MYC½ þ MYC@Ebox½  þ MYC@NNNNNN½ 
þ MYC@EboxWDR5½ þ MYC@NNNNNNWDR5½ 
(16)
Eboxtotal½  ¼ Eboxunbound½ þ MYC@Ebox½  (17)
NNNNNNtotal½  ¼ NNNNNNunbound½ þ MYC@NNNNNN½  (18)
EboxWDR5total½  ¼ EboxWDR5unbound½ þ MYC@EboxWDR5½  (19)
NNNNNNWDR5total½  ¼ NNNNNNWDR5unbound½ þ MYC@NNNNNNWDR5½  (20)
The hexamer sequence NNNNNN excludes the CACGTG sequence. Eboxtotal excludes
CACGTG sequences in the vicinity of WDR5 (EboxWDR5total).
Rates
v1 ¼ k1  MYC½   Eboxunbound½  (21)
v1r ¼ k 1  MYC@Ebox½  (22)
v2 ¼ k2  MYC½   NNNNNNunbound½  (23)
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v2r ¼ k 2  MYC@NNNNNN½  (24)
v3 ¼ k3  MYC½   EboxWDR5unbound½  (25)
v3r ¼ k 3  MYC@EboxWDR5½  (26)
v4 ¼ k4  MYC½   NNNNNNWDR5unbound½  (27)
v4r ¼ k 4  MYC@NNNNNNWDR5½  (28)
Steady state assumption
d MYC@Ebox½ 
dt
¼ 0 (29)
d MYC@NNNNNN½ 
dt
¼ 0 (30)
d MYC@EboxWDR5½ 
dt
¼ 0 (31)
d MYC@NNNNNNWDR5½ 
dt
¼ 0 (32)
The ratios of dissociation and association rate constant are substituted by the dissociation
constants KEbox ¼
k 1
k1
, KNNNNNN ¼
k 2
k2
, KEboxWDR5 ¼
k 3
k3
, and KNNNNNNWDR5 ¼
k 4
k4
.
Definition of occupancy
Occupancy of E-boxes is defined by the proportion of E-boxes bound by MYC in total number
of E-boxes in percentage at steady state:
occupancyEbox ¼
MYC@Ebox½ 
Eboxtotal½ 
 100%:
Likewise, occupancy of NNNNNN sequences, of Ebox-WDR5 and NNNNNN-WDR5 binding
sites are given by
occupancyNNNNNN ¼
MYC@NNNNNN½ 
NNNNNNtotal½ 
 100% ,
occupancyEboxWDR5 ¼
MYC@EboxWDR5½ 
EboxWDR5total½ 
 100% , and
occupancyNNNNNNWDR5 ¼
MYC@NNNNNNWDR5½ 
NNNNNNWDR5total½ 
 100% , respectively.
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Remark on steady state assumption
Our modelling approach partially builds on data of ChIP-sequencing experiments. ChIP-
sequencing experiments are based on the general notion that the number of DNA-bound
molecules (tags) presumably does not change (at least) for the time frame of conducting the
experiment. We therefore use the steady state assumption for calculating apparent
dissociation constants, which imply ratios on dissociation and association rate constants.
Parameters
The amount of MYCtotal is varied up to 4.610
6 molecules, which is the maximal amount
experimentally measured in U2OS cells under different treatments (EtOH, Dox, and siRNA;
see Supplementary file 1).
The following tables (Appendix 1—table 1, Appendix 1—table 2 and Appendix 1—table 3)
list all parameters used in model 1 and 2.
Appendix 1—table 1. Parameters generally applicable to models 1 and 2.
Parameter Value Unit Comment, Reference
Vol 7.710–13 L 1)
Genometotal 9.510
9 base pairs 2)
DOI: 10.7554/eLife.15161.020
Appendix 1—table 2. Parameters of model 1.
Parameter Value Unit Comment, Reference
Eboxtotal 9.310
5 molecules 3)
NNNNNNtotal 9.510
9 molecules 4)
KEbox 4.610
1 molecules 5); 0.1 nM (Guo et al., 2014)
KNNNNNN 9.310
3 molecules 5); 20 nM (Guo et al., 2014)
DOI: 10.7554/eLife.15161.021
Appendix 1—table 3. Parameters of model 2.
Parameter Value Unit Comment, Reference
Eboxtotal 9.210
5 molecules 6)
NNNNNNtotal 9.510
9 molecules 6)
EboxWDR5total 1.210
4 molecules 6)
NNNNNNWDR5total 4.710
4 molecules 6)
KEbox 4.610
1 molecules 5); 0.1 nM (Guo et al., 2014)
KNNNNNN 9.310
3 molecules 5); 20 nM (Guo et al., 2014)
KEboxWDR5 4.310
–4 molecules 7)
KNNNNNNWDR5 8.610
–2 molecules 7)
DOI: 10.7554/eLife.15161.022
Comments
1. Walz, Lorenzin et al. show that Dox-induced MYC is predominantly localized in U2OS cell
nuclei ([Walz et al., 2014], extended data Figure 1B). We therefore consider only the
nuclear volume of an U2OS cell. The nucleus dimensions were quantified as approximately
16 mm in width, 23 mm in length, and 4 mm in height (Koch et al., 2014). We assumed an
ellipsoid to calculate the volume of an U2OS cell nucleus.
2. Genometotal is the number of considered base pairs estimated for the female hypertriploid
karyotype of U2OS cells. Total base pairs are counted in the haploid unmasked human ref-
erence genome hg19 without taking the Y chromosome into account and excluding ’N’ and
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’chrN_random-sequences’. The number is multiplied by 2 to account for diploid cells and
subsequently multiplied by a factor of 1.7 (Ben-Shoshan et al., 2014) to account for the
hypertriploid karyotype of U2OS cells (http://www.lgcstandards-atcc.org/products/all/HTB-
96.aspx#characteristics) (Janssen and Medema, 2013).
3. Eboxtotal is calculated by counting CACGTG sequences in the human reference genome
hg19 without taking the Y chromosome into account and excluding ’N’ and ’chrN_random-
sequences’. The number is multiplied by 2 and 1.7 to account for the karyotype of U2OS
cells.
4. The total number of possible hexameric sequences (NNNNNNtotal) in the genome of U2OS
cells is estimated by subtracting Eboxtotal from Genometotal.
5. To convert the published values of dissociation constants given in [nM] and [mM] into [mole-
cules] the average volume of a single U2OS cell nucleus listed in Appendix 1—table 1 is
used.
6. To obtain Eboxtotal, NNNNNNtotal, EboxWDR5total, and NNNNNNWDR5total, we first down-
loaded processed data of a WDR5-ChIPseq experiment (Thomas et al., 2015) from Gene
Expression Omnibus database (GSE60897), which comprised 17,171 WDR5 peaks. Next, we
identified 27,853 unique RefSeq-TSS (USCS, hg19.refGene), which enumerated to 22,346
promoters assuming –1.5 kb to +0.5kb as promoter region and joining overlapping pro-
moter regions. 3,408 of these 22,346 promoters contain WDR5 as well as a CACGTG
sequence. This number (3,408) is multiplied by 2 and 1.7 to account for the karyotype of
U2OS cells yielding EboxWDR5total. Eboxtotal is given by subtracting EboxWDR5total from
Eboxtotal listed in Appendix 1—table 2. NNNNNNWDR5total is calculated by subtracting
EboxWDR5total from all called WDR5 peaks (i.e., 17,171 WDR5 peaks multiplied by 2 and
1.7 to account for U2OS cell karyotype). NNNNNNtotal results from subtracting the sum
of Eboxtotal, EboxWDR5total, and NNNNNNWDR5total from Genometotal.
7. The dissociation constant of MYC and EboxWDR5 is estimated by multiplying the individual
dissociation constants of MYC and WDR5 (9.310–6 M; [Thomas et al., 2015) as well as
MYC and E-boxes (0.110–9 M; [Guo et al., 2014]). This approach is based on our presump-
tion that under constant pressure the standard change of Gibbs free energy at equilibrium
of reversible binding of MYC to EboxWDR5 is equal to the sum of the standard change of
Gibbs free energies at equilibria of reversible MYC-WDR5-association and reversible MYC-
CACGTG-association. Similarly, the dissociation constant of MYC and NNNNNNWDR5 is
estimated by multiplying the individual dissociation constants of MYC and WDR5 (9.3106
M; (Thomas et al., 2015]) as well as MYC and unspecific DNA (20109 M; [Guo et al.,
2014]).
Lorenzin et al. eLife 2016;5:e15161. DOI: 10.7554/eLife.15161 30 of 35
Research article Cancer Biology Cell Biology
Appendix 2
Appendix 2 provides an extended analysis and discussion of the modelling approach.
Motivation and aims
The mathematical models introduced in the manuscript consider two kinds of parameters:
dissociation constants (KEbox, KNNNNNN , KEboxWDR5, and KNNNNNNWDR5) and total numbers of
molecules and binding sites ( MYCtotal½ , Eboxtotal½  , NNNNNNtotal½ , EboxWDR5total½  , and
NNNNNNWDR5total½ ). In Appendix 1, we provide a particular set of parameter values for each
model. Here, in Appendix 2, we use model 1 to comprehensively dissect the impact of model
parameters on the occupancy of E-boxes by MYC. We investigate:
1. how the occupancy of E-boxes by MYC depends on the total number of MYC molecules
allowing for a wide range of dissociation constants KNNNNNNN and KEbox , and
2. to what extend this dependency is affected by variations of E-box and NNNNNN sequence
counts to estimate the impact of heterochromatin or altered karyotype.
Summary of results
Our comprehensive analysis reveals that a higher affinity of MYC to E-boxes than NNNNNN
sequences is sufficient to observe higher occupancy of E-boxes than of NNNNNN sequences
by MYC in the measured range of MYC abundance. Second, we demonstrate that the
dependence of E-boxes occupancy and NNNNNN sequence occupancy on MYC in the
measured range of MYC abundance is strongly influenced by the ratio of the respective
dissociation constants. Finally, we show that a variation of the number of E-boxes and
NNNNNN sequences to account for heterochromatin or deviation of karyotype hardly affects
our results.
Discussion of the parameters of model 1
As mentioned above, five parameters characterize model 1: KEbox , KNNNNNN , Eboxtotal½ ,
NNNNNNtotal½ , and MYCtotal½ . Since the values of Eboxtotal½  and NNNNNNtotal½  are relatively
defined for a given genome, we will initially fix Eboxtotal½  to 9.310
5 and NNNNNNtotal½  to
9.5109 in our analysis to reduce parameter space. These values are calculated from human
reference genome (hg19) assuming the karyotype of U2OS cells (see comments in Appendix
1). In a second step, we will extend our analysis to investigate the impact of other values of
total number of E-boxes and NNNNNN sequences to take heterochromatin and karyotype
alterations into account.
The values of MYCtotal½  were experimentally determined to range from 7.110
3 to 4.6106
molecules (Supplementary file 1). Therefore, MYCtotal½  is varied in our analyses over orders of
magnitude on a logarithmic scale from 3103 to molecules.
The values of the dissociation constants KNNNNNN and KEbox are varied over a very wide range
(from 10–7 to 107 molecules) in this analysis to cover all possible conditions.
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Results of the model analysis
Conditions for higher occupancy of E-boxes than of NNNNNN
sequences
Appendix 2–figure 1 illustrates regions of certain occupancy in the three dimensional
parameter space of dissociation constants KNNNNNN and KEbox as well as total amount of MYC
MYCtotal½ . It shows that higher occupancy of E-boxes (Appendix 2–figure 1A) than of
NNNNNN sequences (Appendix 2–figure 1B) is observable for most combinations of
dissociation constants KNNNNNN and KEbox in the considered range of total amount of MYC. For
instance, occupancy of E-boxes can reach 90% at MYCtotal½  values in the order of 10
6
molecules. In contrast, the occupancy of NNNNNN sequences is generally low in the order of
0.1% or less. This is mainly due to the vast excess of NNNNNN sequences compared to
E-boxes.
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Appendix 2–figure 1. Plot shows surfaces of equal occupancy as function of dissociation
constants KNNNNNN and KEbox as well as total amount of MYC. Different regions of occupancy of
E-boxes (A) and NNNNNN sequences (B) are shown in this parameter space. The
experimentally measured range of the total amount of MYC is marked in grey. Total MYC
concentrations of U2OS cells were changed by different experimental treatments as indicated
on the upper axis. To simulate U2OS cells, Eboxtotal½  ¼ 9:3  10
5 and NNNNNNtotal½  ¼ 9:5  10
9 are
assumed.
DOI: 10.7554/eLife.15161.023
Appendix 2–figure 2 shows the parameter space of Appendix 2–figure 1A from two
different perspectives, i.e. rotated into the MYCtotal½ -KEbox -plane and into the KEbox-KNNNNNN-
plane. For simplification only the surface of 50% occupancy of E-boxes by MYC is shown.
Looking from these two perspectives, it seems that a critical total amount of MYC is necessary
to observe occupancies above 50% and the dissociation constant KNNNNNN must be larger than
the dissociation constant KEbox. Indeed, an analytical analysis proofs (see below) that
KNNNNNN>KEbox is both a necessary and a sufficient condition to observe
occupancyEbox>occupancyNNNNNN . This implies that even in the case of small differences in the
dissociation constants of MYC to E-boxes and NNNNNN sequences, differential occupancies
occur.
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Appendix 2–figure 2. Plot shows surface of occupancyEbox ¼ 50% of Appendix 2–figure 1A in
two different orientations: rotated into the MYCtotal½ -KEbox -plane and into the KEbox-KNNNNNN -
plane.
DOI: 10.7554/eLife.15161.024
The ratio of both dissociation constants impacts the difference
between occupancies of E-boxes and NNNNNN sequences
Next, we investigate how strongly the occupancies of E-boxes and NNNNNN sequences can
differ. To explore whether absolute values or ratios of the dissociation constantsKNNNNNN and
KEbox play an important role to separate the two occupancy curves, we vary the value of KEbox as
well as the ratio of KNNNNNN toKEbox in a systematic fashion (Appendix 2–figure 3). We observe
that for a given value of KEbox, the difference between the occupancy of E-boxes andNNNNNN
sequences is the greater, the greater the ratio of KNNNNNN to KEbox . Moreover, for a given ratio of
the dissociation constants, the value of KEbox hardly impacts the occupancy curves. This
demonstrates that the ratio of the dissociation constants but not their absolute values
predominantly determines whether distinct occupancies of E-boxes and NNNNNN sequences
can be observed. Please note that the changes of KEbox in the calculations for Figure 3E
simultaneously changed the ratio of KNNNNNN to KEbox and therefore affected the EC50 value.
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Appendix 2–figure 3. Ratio of the dissociation constants KNNNNNN and KEbox determines how
much occupancy of E-boxes differs from occupancy of NNNNNN sequences. The panels show
the dependency of the occupancies of E-boxes (red curve) and NNNNNN sequences (blue
curves) on total number of MYC molecules. For each panel a different combination of
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dissociation constants KNNNNNN and KEbox are chosen. The panels are displayed in a matrix
sorted for increasing values of KEbox and increasing ratios KNNNNNN to KEbox.
DOI: 10.7554/eLife.15161.025
Variations of number of E-boxes and NNNNNN sequences hardly
affect the previous results
So far, a fixed number of E-boxes and NNNNNN sequences was considered in the simulations
( Eboxtotal½  ¼ 9:3  10
5 and NNNNNNtotal½  ¼ 9:5  10
9). Taking into account that the euchromatic
sequencemakes up approximately 90% of the human genome (International HumanGenome
Sequencing Consortium, 2004) and the karyotype of U2OS cells substantially differs from that of
normal human cells (Ben-Shoshan et al., 2014), the impact of the number of E-boxes and
NNNNNN sequences on occupancy of E-boxes is now investigated. The analysis shows that a
change in the numbers of E-boxes and NNNNNN sequences hardly affects the occupancy of
E-boxes with respect to total MYC (Appendix 2–figure 4).
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Appendix 2–figure 4. Impact of number of E-boxes and NNNNNN sequences. Different
combinations of number of E-boxes and NNNNNN sequences are assumed in the simulations:
Eboxtotal½  ¼ 9:3  10
5 and NNNNNNtotal½  ¼ 9:5  10
9 represent the reference values and the range
of 50% to 200% of these reference values is taken into account. Surfaces of equal occupancy
of E-boxes are shown as function of dissociation constants KNNNNNN and KEbox as well as total
amount of MYC.
DOI: 10.7554/eLife.15161.026
Proof
Using equations 1–11 (Appendix 1), we derive the following equation system:
0¼ MYC½   1  occupancyEboxð Þ KEbox  occupancyEbox
0¼ MYC½   1  occupancyNNNNNNð Þ KNNNNNN  occupancyNNNNNN








This yields expressions of KNNNNNN and KEbox:
KEbox ¼ MYC½  
1 occupancyEboxð Þ
occupancyEbox
KNNNNNN ¼ MYC½  
1 occupancyNNNNNNð Þ
occupancyNNNNNN
Assuming KNNNNNN>KEbox holds, then
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) 1 occupancyNNNNNNð Þ
occupancyNNNNNN
> 1 occupancyEboxð Þ
occupancyEbox
) occupancyEbox>occupancyNNNNNN
Similarly it can be proven that if occupancyEbox>occupancyNNNNNN then KNNNNNN>KEbox holds.
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